Calm vs Hims & Hers
Side-by-side comparison of AI visibility scores, market position, and capabilities
Calm is a leading mental wellness app offering sleep, meditation, and relaxation content with enterprise health benefits programs serving over 100 million downloads.
About
Calm is a digital mental health company founded in 2012 by Michael Acton Smith and Alex Tew that has grown into one of the most downloaded and highest-grossing health apps globally. The platform offers guided meditations, sleep stories narrated by celebrities, breathing exercises, and relaxing music designed to reduce stress, improve sleep quality, and support overall mental wellness. Calm has exceeded 100 million downloads and reached a $2B valuation with backing from TPG, making it one of the most valuable standalone consumer wellness applications. The company has expanded into enterprise with Calm Business, providing employee mental health and wellbeing benefits to thousands of organizations. Calm has invested heavily in content production, partnering with prominent voices including LeBron James, Matthew McConaughey, and Harry Styles for exclusive audio content. The company also offers Calm Kids with age-appropriate mindfulness content for children. While positioned primarily as a consumer wellness tool rather than a clinical platform, Calm's scale and brand recognition have made it a leading solution for companies seeking accessible, low-friction mental wellness benefits for large employee populations.
Consumer telehealth platform with Q3 2025 revenue of $599M (+49% YoY); 2.47M subscribers; 2025 guidance $2.3-2.4B; acquiring ZAVA for European expansion; GLP-1 weight loss, hair, and sexual health treatments shipped directly to subscribers.
About
Hims & Hers is a consumer telehealth and pharmacy platform founded in 2017 in San Francisco by Andrew Dudum, built on the mission of making high-quality healthcare affordable and stigma-free for conditions that people historically avoided treating due to embarrassment, cost, or access barriers. The platform's core technology combines a direct-to-consumer digital health interface with an integrated pharmacy network, enabling patients to complete asynchronous or synchronous consultations with licensed clinicians and receive prescription treatments — including compounded medications — delivered directly to their homes.\n\nHims & Hers serves patients across sexual health, hair loss, mental health, dermatology, and weight management. The company's expansion into GLP-1 compounded weight loss medications has been a significant growth catalyst, capitalizing on surging consumer demand for semaglutide and tirzepatide alternatives during periods of branded drug shortages. With 2.47 million subscribers and a subscription-centric business model, the platform generates predictable recurring revenue from patients on ongoing treatment protocols. The company's 2025 acquisition of ZAVA expands its addressable market into European telehealth markets.\n\nHims & Hers reported Q3 revenue of $599 million, a 49% year-over-year increase, and issued full-year 2025 guidance of $2.3 to $2.4 billion — a scale that makes it one of the largest consumer telehealth companies in the world. The company's ability to compound subscriber growth with expanding treatment categories and international expansion through ZAVA provides multiple vectors for continued revenue acceleration. As healthcare consumerization intensifies and patients increasingly manage chronic conditions through digital-first platforms, Hims & Hers' brand recognition, integrated pharmacy infrastructure, and subscription model give it a durable position in consumer health.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.